

## CLAIMS

- sub. B17
1. An LAK activity enhancer containing an extract of *Lentinus edodes* mycelium.
  2. The LAK activity enhancer of claim 1 for enhancing LAK activity by acting on lymphocytes derived from peripheral blood.
  3. The LAK activity enhancer of claim 2 containing an extract of *Lentinus edodes* mycelium at a concentration of 1  $\mu\text{g}$  or more per  $10^6$  lymphocytes.
  4. An LAK activity-enhancing formulation containing the LAK activity enhancer of claim 1.
  5. A pharmaceutical or veterinary LAK activity-enhancing formulation comprising the LAK activity enhancer of claim 1 and a pharmaceutically acceptable carrier.
  6. The LAK activity-enhancing formulation of claim 4 or 5 for oral administration.
  7. The LAK activity-enhancing formulation of claim 4 in the form of a food, drink or feed.
  8. The LAK activity-enhancing formulation of claim 4 or 5 for injection or percutaneous administration.
  9. The LAK activity-enhancing formulation of any one of claims 4 to 8, wherein said formulation is used for treating tumor and/or cancer.
  10. A method for treating tumor and/or cancer comprising administering an effective amount of the LAK activity-enhancing formulation of any one of claims 4 to 8.
  11. A use of the LAK activity enhancer of claim 1 for the preparation of a drug used for treating tumor and/or

<sup>18</sup>  
cancer.

Add B2